Andreessen Horowitz Leads $22M in Funding for Thyme Care to Improve Patient Outcomes, Close Gaps in Health Disparities, and Drive Value-Based Cancer Care
Thyme Care, an oncology care management solution providing high-touch, tech-enabled cancer care navigation, recently announced it closed $22 million in funding led by Andreessen Horowitz, AlleyCorp, and Frist Cressey Ventures with participation from Casdin Capital and Bessemer. The capital will be used to accelerate Thyme Care’s technology and advance partnerships with oncologists, health plans, employers, and risk-based entities.
Thyme Care was founded by oncology industry veterans and clinicians all personally impacted by cancer, with a shared mission to transform the cancer experience and improve the quality of life for individuals diagnosed with cancer. With deep expertise in healthcare technology and cancer care, the Thyme Care team is building navigation services that combine human-first support and an extensive oncology network enabled by scalable, intuitive technology. The company’s platform is the first in the industry to generate actionable insights that enable the identification of individuals early in the cancer journey while optimizing the patient experience and empowering clinicians to be able to better serve patients’ needs at scale.
“As someone who has spent 15 years working in oncology, I’m shocked at the difference in the patient experience between a person that has a friend or family member working in oncology and someone who is left to figure it out on their own. An insider can make the difference,” said Robin Shah, Thyme Care’s CEO and Founder. “Everyone deserves to have the best access to care and our health shouldn’t be determined by the personal relationships we have. We created Thyme Care to be that insider and patient companion from the start, and a knowledgeable support system throughout the entire cancer journey, for everyone.”
